《科學美國人》
· 谷歌DeepMind發布用於藥物發現的升級版AlphaFold3近兩年後，其生物製藥子公司Isomorphic Labs宣布推出一款功能更強大的AI模型——但他們卻秘而不宣。
總部位於倫敦的Isomorphic Labs在2月10日發布的一份27頁技術報告中，大力宣傳了其「藥物發現引擎」（簡稱IsoDDE）的功能。該引擎的成果，包括精確預測蛋白質與潛在藥物的相互作用以及抗體結構，給該領域的科學家留下了深刻印象。
然而，與AlphaFold用於預測蛋白質結構的AI系統（該系統已向其他研究人員開放，並在期刊文章中進行了深入描述）不同，IsoDDE是專有的，而且這份技術報告幾乎沒有提供任何關於如何實現類似結果的見解。 http://spklr.io/6042DsmSE
✍：Ewen Callaway 和《自然》雜誌
📸：同構實驗室
美國公共廣播公司新聞時間
Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful artificial-intelligence model — and they’re keeping it all to themselves.
Isomorphic Labs, based in London, touted the capacities of its ‘drug-discovery engine’ — which it calls IsoDDE — in a 27-page technical report, released on 10 February. Achievements, including precise predictions of how proteins interact with potential drugs and antibody structures, have impressed scientists working in the field.
Yet unlike the AlphaFold AI systems for predicting protein structure — which were made accessible to other researchers and described in depth in journal articles — IsoDDE is proprietary, and the technical paper offers scant insight into how to achieve similar results.
http://spklr.io/6042DsmSE
: Ewen Callaway & Nature Magazine
: Isomorphic Labs
沒有留言:
張貼留言